Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks IPOs and placings
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Diaceutics appoints new VP of marketing
(Sharecast News) - Diaceutics, a technology and solutions provider catering to the pharmaceutical and biotech industry, announced the appointment of Amie Mc Neice as vice-president of marketing on Tuesday. The AIM-traded firm said Mc Neice, with a background in senior marketing and business development roles at organisations including Almac Group, Fibrus and Kingspan, would bring extensive leadership experience to her new role.
In her capacity as vice-president of marketing, she would spearhead the execution of Diaceutics' three-year marketing vision, focusing on brand positioning, messaging, and the integration of marketing automation.
Notably, her experience in collaborating with US pharma customers would be instrumental in furthering Diaceutics' market presence.
"I am delighted to welcome Amie to the team at Diaceutics," said chief commercial officer Jillian Beggs.
"Our continued investment in sales and marketing supports our mission to provide the data, technology solutions and insights that enable our pharma and biotech customers revolutionise the commercialisation of their products and ultimately improve patient outcomes."
Aligned with its commitment to expanding sales and marketing capabilities in the US and Europe through 2024, Diaceutics said it was "dedicated" to bolstering its team with top-tier talent.
Additionally, it was continuing to invest in product development, exemplified by the ongoing expansion of its product management team in 2024.
The board said the team would play a pivotal role in executing the company's product roadmap and coordinating various product activities across data, scientific and medical services, engagement solutions, engineering, and marketing.
"I have long admired Diaceutics and look forward to working with the team as we expand our sales and marketing capabilities and serve our customers' needs across the US and Europe," commented Amie Mc Neice.
At 1436 BST, shares in Diaceutics were up 0.03% at 104.03p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity and Inclusion | Doing Business with Fidelity | Fidelity gender pay report | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Security | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.
